This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	Histone deacetylase (HDAC)	<p>Mouse studies suggest that HDAC inhibitors may help treat glucocorticoid-resistant ALL. In mice bearing dexamethasone-resistant ALL cells derived from patients, co-treatment with dexamethasone and the HDAC inhibitor Zolinza vorinostat significantly prolonged progression-free survival compared with dexamethasone alone ($p=0.005$) or Zolinza alone ($p=0.001$). Next steps include identifying the molecular determinants that predict whether a patient might benefit from this combination treatment.</p> <p>Merck & Co Inc. markets Zolinza vorinostat to treat cutaneous T cell lymphoma (CTCL).</p> <p>SciBX 3(31); doi:10.1038/scibx.2010.945 Published online Aug. 12, 2010</p>	Unpatented; licensing status not applicable	<p>Bachmann, P.S. <i>et al. Blood</i>; published online July 20, 2010; doi:10.1182/blood-2010-05-284968</p> <p>Contact: Richard B. Lock, The University of New South Wales, Sydney, New South Wales, Australia e-mail: rlock@ccia.unsw.edu.au</p>